Here’s what you should know.
1. The study will assess the safety, efficacy and tolerability of the joint therapy approach for NASH.
2. NASH is the fastest growing cause of liver cancer and liver transplants in the United States.
3. Allergan did not disclose terms of the deal.
4. There are currently no treatments for NASH.
More articles on gastroenterology:
University of Arizona researchers making dual-view endoscope: 3 key notes
Payment Model Technical Advisory Committee approves Project Sonar as an alternative payment model
GI leader to know: Dr. Brent Gray of Central Texas Gastroenterology Consultants
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.